# Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

> **NCT05375825** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Malignant Pleural Mesotheliomas (Mpm)
- Malignant Pleural Effusions (Mpe)
- Epithelial Tumors, Malignant
- Pleural Effusions, Malignant
- Mesothelin (Msln)

## Interventions

- **PROCEDURE:** Cytoreductive surgery
- **DRUG:** LMB-100
- **DIAGNOSTIC_TEST:** Immunohistochemical Assay for Mesothelin

## Key facts

- **NCT ID:** NCT05375825
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-31
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants enrolled.
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375825, "Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05375825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*